目的：了解丙型肝炎病毒抗体诊断试剂(胶体金法)在生产、流通、使用环节的总体质量情况，为丙型肝炎病毒抗体诊断试剂(胶体金法)的质量监测及质量管理提供参考。方法：用抽验试剂根据行业标准YY/T 1215—2013规定的丙型肝炎病毒抗体快速检测试剂国家参考品进行检测，并用 WHO HCV Seroconversion Panel PHV917(M)HCV Genotype 2b 和 HCV Hepatitis C Seroconversion Panel PHV919 (0610-0217)HCV Genotype 1a血清转换盘对部分产品进行检测，比较不同产品灵敏度差异。 结果与结论：按行业标准生产的34批抽验样品中33批符合行业标准YY/T 1215—2013要求，但对WHO HCV系列血清检测阳转时间有差异，另有1批因无法加样而不符合要求，说明国产丙型肝炎病毒抗体检测试剂(胶体金法)总体质量较好，但试剂灵敏度有差异；本次抽验涉及20个批准文号，占全部该类企业批准文号的50%，建议以后扩大抽样覆盖范围并研制丙型肝炎病毒系列血清转换盘。
Objective: To understand the overall quality of Anti-HCV Colloidal Gold-based Immunoassay Kits in the process of production, circulation and use for the benefit of the quality control and supervision. Methods: Sampling reagents were tested according to the national reference material for rapid detection of anti-HCV Colloidal Gold-based Immunoassays stipulated by the trade standard YY/T 1215—2013. Some products were tested with WHO Seroconversion Panel PHV917(M)HCV Genotype 2b and Seroconversion Panel PHV919 (0610-0217)HCV Genotype 1a to compare the sensitivity differences of different sample kits. Results and Conlusion: Of the 34 batches of samples which were produced according to the industry standards, 33 batches met the requirements of industry standard YY/T 1215-2013 although the positive conversion time was different in the serum detection of WHO HCV series. One batch did not meet the requirements due to the inability to add samples, indicating that the overall quality of domestic Anti-HCV Colloidal Gold-based Immunoassay Kits was good, although the sensitivity of the sample reagents was different. This sampling test has involved 20 approvalnumbers, accounting for 50% of the total approval numbers for such enterprises. It is suggest to extend the sampling scope and develop a series of national HCV Seroconversion Panels.
[1] Choo QLKG,Weiner AJ,Overby LR,et al.Isolation of a cDNA Clong Derived from a Blood-borne Non-A,Non-B Viral Hepatitis Genome[J].Science,1989,244:359-362.
[2] Kato N.Genome of Human Hepatitis C Virus(HCV):Gene Organization,Sequnce Diversity and Variation[J].Microb Comp Genomics,2000,5(3):129-151.
[3] Hollinger.Non-A,Non-B Hepatitis Viruses[M]//Virology,New York:Rave Press,1990:2239-2273.
[4] Houghton M.The Long and Winding Road Leading to the Identification of the Hepatitis C Virus[J].Hepatol,2009,51(5):939-948.
[5] 俞海燕.免疫层析试验的临床应用进展[J].临床检验信息,1998,5:118-120.
[6] 陶义训.免疫测定进展[J].上海免疫学杂志,1999,19(2):65-68.
[7] Beelaert G,Vercauteren G,Fransen K,et al.Comparative Evaluation of Eight Commercial Enzyme Linked Immunosorbent Assays and 14 Simple Assays for Detection of Antibodies to HIV[J].J Virol Med,2002,105:197-206.
[8] 李秀华,宋爱京,王佑春.HIV抗体快速诊断试剂与酶联免疫诊断试剂灵敏度比较[J].中国生物制品学杂志,2004,17(3):175-176.
[9] YY/T 1215-2013 中华人民共和国医药行业标准[S].2013.
[10] 于洋,谷金莲,梁争论.丙型肝炎病毒抗体诊断试剂盒专项抽验情况分析及建议[J].中国药事,2015,29(7):687-693.
[11] 李茜,刘英,闻京伟,等.硫酸卷曲霉素的质量评价及标准提高研究[J].中国药事,2014,28(8):858-864.
[12] 申兰慧.复方氯已定含漱液评价性抽验结果及质量评价 [J].中国药事,2014,28(2):125-127.
[13] 陈显,黄成垠,朱绍汶.丙型病毒性肝炎的基因分型方法及临床意义[J].临床输血与检验,2012,14(1):89-91.
[14] 祁自柏,周诚,杨振.对两种第三代丙肝试剂检测的不同功能区抗体组分研究[J].中华微生物学和免疫学杂志,1999,19(5):433-435.
[15] 陶钧,刘勇,童毅.贵州吸毒人群丙型肝炎病毒感染者的基因分型研究[J].中国病毒病杂志,2012,2(2):117-122.
[16] Dow BC,Munro H,Buchanan I,et al.Third-generation of Recombinant Immunoblot Assay:Comparision of Reactivities According to Hepatitis C Virusgenotype[J].Transfusion,1996,36(6):547-551.
[17] 于洋,祁自柏,周诚,等.国产抗HCV酶联免疫诊断试剂[J].中国预防医学杂志,2001,3(2):168-170.
[18] 于洋,祁自柏,周诚,等.国产抗HCV EIA试剂漏检原因分析[J].中国药事,2003,5(17):300-302.
